# Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

> **NCT02477215** · PHASE1,PHASE2 · COMPLETED · sponsor: **Parameswaran Hari** · enrollment: 38 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MLN9708
- **DRUG:** Dexamethasone
- **DRUG:** Bendamustine (multiple dose levels)
- **DRUG:** Bendamustine (MTD)

## Key facts

- **NCT ID:** NCT02477215
- **Lead sponsor:** Parameswaran Hari
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-09
- **Primary completion:** 2018-05-02
- **Final completion:** 2020-09-17
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477215, "Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02477215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*